Identifying undervalued growth stocks can lead to significant returns. CRISPR Therapeutics (NASDAQ: CRSP) has faced challenges but remains promising due to its gene therapy approvals, potential revenue, and diverse portfolio. Consider investing in this well-funded biotech for long-term growth potential.